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dose-speciﬁc efﬁcacy of SPAA at reducing systolic blood pressure
and total cholesterol were drawn from published clinical trial
data (RESPOND), while costs were sourced from Korean phar-
maceutical pricing lists. SPAA comprised weighted average doses
of the ﬁxed-dose combinations of amlodipine 5 mg / atorvastatin
10 mg and 5 mg/20 mg, based on market distribution in Korea.
A 20% price reduction after one year was implemented to reﬂect
patent expiry. Costs of CVD were derived from 2008 Korean
Health Insurance Review and Assessment Service (HIRA) esti-
mates. Utility values for CVD were obtained from published
literature based on 2005 KNHANES data. RESULTS: Compared
to placebo (no treatment), the incremental cost-effectiveness
ratios associated with SPAA were 1,428,681 Korean won (KW)/
QALY and 1,989,858 KW/YoLS. (One thousand KW equates to
approximately one US dollar.) Sensitivity analyses indicated these
results to be robust. CONCLUSIONS: SPAA represents a cost-
effective strategy for the primary prevention of CVD in Korea.
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OBJECTIVES: Chronic heart failure (CHF) is associated with a
substantial clinical and economic burden that impacts signiﬁ-
cantly on health care systems. The objective of this study is to
assess the cost-utility of a new home telemonitoring (HTM)
project in elderly CHF outpatients. METHODS: This prospec-
tive, 6-month, randomised trial was designed to compare the
cost-effectiveness of a HTM project versus usual care (UC) in
elderly patients with CHF, receiving optimal treatment and coun-
selling. A total of 24 patients (aged 66–92 years) were assigned
randomly to HTM or UC. At baseline and at the end of the study,
all patients had a complete cardiologist’s assessment, including
quality of life. The evaluation of the cost of HTM includes the
cost of drug therapy, monitoring, treating side-effects, hospital-
izations and devices. All costs were calculated from a third-party
payer perspective, in 2007 Euros. RESULTS: The mean duration
of the follow-up was similar for the two groups (136.92  36.65
days, P > 0.05). There was a non-statistically signiﬁcant reduc-
tion in hospital readmissions, hospitalisation days, physicians’
visits, laboratory tests and total costs (P > 0.05) for HTM group.
However, HTM was associated with a signiﬁcant improvement
in the QoL measured with the generic health-related EQ-5D
questionnaire (10.00  7.24, P < 0.001) and a small incremental
gain of 0.13  0.24 quality-adjusted-life-years (QALYs) over
UC. The analysis showed that the average incremental cost of
HTM was €12,909  €53,313/QALY gained. CONCLUSIONS:
HTM is likely to be a cost-effective intervention compared with
UC in elderly CHF outpatients in Greece. However, further
studies with more patients and longer duration are needed to
conﬁrm these results.
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OBJECTIVES: To investigate the potential beneﬁt of adding
genetic testing to a pharmacist-managed anticoagulation service
for hospitalized patients on warfarin. METHODS: Using deci-
sion analytic modeling we constructed a decision tree model. The
decisions used were a treat-all and a treat-none approach. The
outcome of interest was minimizing the number of adverse events
(bleeding or thrombitic event). Model parameters were primarily
based on institutional data. Additional information from the
literature or expert opinion was used if needed. One-way sensi-
tivity analyses were performed on unknown parameters to deter-
mine decision thresholds. Two parameters, percentage of patients
beneﬁting from testing and rate of reduction of adverse event
rates due to genetic test results, were given special attention as no
prior information is available. Probabilistic sensitivity analysis
was also conducted. A willingness-to-pay of $35,000 per avoided
adverse event was used as the decision threshold. RESULTS:
Sensitivity analysis showed the decision choice to be affected by
the values of both parameters of interest (20% prevalence and
8% reduction respectively). Baseline analysis resulted in the
treat-all approach to cost an additional $102 per patient on
average and avoid 8 adverse events per 10,000 patients. Proba-
bilistic analysis determined the point at which each decision was
equally likely to be optimal was at a willingness-to-pay of
$140,000. Holding the reduction rate constant the rate of
patients beneﬁtting from the test would need to be as high as
40% before the treat-all approach becomes optimal. Similarly,
the reduction rate would need to be as high as 16% for the
treat-all approach to be optimal. CONCLUSIONS: The percent-
age of patients that would beneﬁt from testing, as well as the
reduction in adverse event rates due to testing, inﬂuence the
decision of treatment approach. The addition of testing all
patients could potentially be cost-effective with sufﬁciently high
enough prevalence and adverse event reduction rates.
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OBJECTIVES: Contrast-induced adverse drug reactions (ADRs),
including contrast-induced nephropathy, are common among
high-risk patients undergoing angiography (e.g., patients with
diabetes mellitus and renal impairment). These ADRs cause
extended hospital stays and additional medication use, leading to
increased cost. We examine the cost-effectiveness of the use of 2
contrast media, in patients at high risk of contrast-induced ADRs,
from the perspective of 5 European countries (Germany, Italy,
Spain, Sweden, and UK). METHODS: A multi-country decision-
analytic model was constructed to estimate the cost-effectiveness
of an isosmolar contrast agent (iodixanol) compared to a low-
osmolar contrast medium (iohexol). The emphasis of the model
was to consider differences in the incidence of severe ADRs in
patients at high risk of contrast-induced nephropathy. The analy-
sis was based on a European randomised controlled trial
(NEPHRIC), in which patients receiving angiography with iodix-
anol had statistically fewer severe ADRs than those with iohexol.
Patients in the study were 18 years of age or older, referred for
coronary or aortofemoral angiography, and had diabetes with
stable serum creatinine concentrations (men: 1.5 to 3.5 mg/dL;
women: 1.3 to 3.5 mg/dL). ADRs considered included acute renal
failure, arrhythmia, cardiovascular events, pulmonary edema, and
multiple-organ failure. Resource use, including hospital days,
medical visits, contrastmedium,medications, laboratory tests and
hospital procedures, were obtained from the NEPHRIC clinical
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trial. Country-speciﬁc unit costs data were obtained from national
sources. Costs are reported in 2007 euro. RESULTS: Iodixanol is
cost-effective compared to iohexol with both lower costs and
better effects related to fewer ADRs. For Germany, Italy, Spain,
Sweden, and UK, respectively, the mean per patient cost differ-
ences due to the reduction in ADRs were €444, €431, €574, €859,
and €753.CONCLUSIONS: Iodixanol results in fewer ADRs and
resulted in lower ADR costs per patient for this high risk patient
population across the ﬁve European countries.
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OBJECTIVES: To determine economic impact of Procoralan®
therapy in stable angina patients as compared to invasive PCI/
CABG therapy. METHODS: A cost-minimisation, probabilistic
model performed from a third party payer perspective in Poland.
Costs calculations were based on the National Health Fund rates.
Invasive therapy cost was assumed to be a weighted average of
PCI/CABG, according to Poland-speciﬁc proportions. Clinical
assumptions and risk proﬁles were derived from the Euro Heart
Survey. The economic impact was calculated for the patients not
qualiﬁed for invasive therapy or maintenance therapy with beta-
blocker due to contraindications or intolerance. Both one-way
(drug cost) and multi-way (revascularisation risk, reimbursement
level) sensitivity analyses were performed. RESULTS: The incre-
mental costs per patient per year were as follows: €747.82–743.34
for Procoralan® 5 mg/7.5 mg therapy respectively; € 3879.88 for
CABG, €2265.88 for PCI. The reduction in payer’s expenditure in
the range of €1918.32–1922.81 per patient per year was demon-
strated as a result of the application of Procoralan® 5 mg/7.5 mg
therapy instead of the invasive therapy. The obtained result applies
to the case of the whole Procoralan® price borne by the payer
(100% reimbursement). In the case of 70% and 50% reimburse-
ment rates savings amounted to €2112.09–2115.23 and
€2248.05–2250.20 depending on dose of the drug. The sensitivity
analyses results showed that change of the Procoralan® treatment
cost (+/-50%), wide range of changes in the risk of a secondary
revascularisation and the reimbursement level did not inﬂuence
the ultimate interpretation of the results. CONCLUSIONS: Third
party payer’s beneﬁts related to Procoralan® may apply to all
patients suffering from angina symptoms having contraindica-
tions or intolerance to beta-blocker. The greatest savings concern
patients not qualiﬁed for invasive therapy as no alternative treat-
ment is effective in this group, but in all scenarios the Procoralan®
therapy was proven to be cost-saving for public payer.
PCV56
AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND
EXPECTANT MANAGEMENT IN WOMEN WITH PREGNANCY-
INDUCED HYPERTENSION OR PREECLAMPSIA ATTERM
(HYPITATTRIAL)
Vijgen SM1, Opmeer BC1, Mol B1, Bijlenga D1, Burggraaff JM2,
van Loon AJ3, Huisjes AJ4, Roumen FJ5, Papatsonis DN6,
van Pampus MG7
1Academic Medical Centre, Amsterdam,The Netherlands, 2Scheper
Hospital, Emmen,The Netherlands, 3Martini Hospital, Groningen,The
Netherlands, 4Gelre Hospital, Apeldoorn,The Netherlands, 5Atrium
Medical Center, Heerlen,The Netherlands, 6Amphia Hospital, Breda,
The Netherlands, 7University Medical Center, Groningen,The
Netherlands
OBJECTIVES: To compare the costs of induction of labor with
the costs of an expectant management strategy in women with
pregnancy-induced hypertension (PIH) or preeclampsia (PE) at
term. METHODS: The Hypertension and Preeclampsia Interven-
tion Trial At Term (HYPITAT) was a multicentre randomized
controlled clinical trial conducted in The Netherlands between
October 2005 and April 2008. Women diagnosed with PIH or PE
at 36 weeks of gestation were randomly allocated to either
induction of labor or expectant management. The study showed
that induction of labor reduced both maternal complications as
well as the caesarean section rate as compared to expectant
management. The economic analysis was performed from a soci-
etal perspective. Resource utilization was documented by speciﬁc
items in the Case Report Forms (CRF) and additional question-
naires. For most medical unit costs, we used estimates provided
by the ﬁnancial and economic departments of two participating
hospitals (one academic and one general hospital). For non-
medical costs and primary care costs Dutch standardized prices
were used. Sensitivity analyses were performed to explore the
impact of different assumptions and cost estimates on the results
of the costs analysis. RESULTS: Data of 756 women were ana-
lyzed. Mean costs per patient were €5400 for induction and
€6025 for expectant management (difference €625). This 10%
difference predominantly originated in the ante partum period:
per patient €977 for induction versus €1929 for expectant man-
agement. Comparable costs were found for delivery (€761 versus
€790 per patient). No substantial differences were found in the
post partum period. CONCLUSIONS: In women with PIH or PE
at term, costs associated with induction of labor are considerably
lower as compared to expectant management. This cost reduc-
tion is mainly due to differences in resource utilization in the ante
partum period.
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OBJECTIVES: To estimate the number and cost of cardiovascu-
lar (CV) events avoided over ﬁve years by treating with statins to
alternative low-density lipoprotein cholesterol (LDL-C) targets
of <3.0 mmol/L and <2.0 mmol/L, based on 1000 patients with
established cardiovascular disease (CVD) or diabetes from an
NHS perspective. METHODS: Proportional effects per mmol/L
LDL-C reduction for non-fatal myocardial infarction (MI), coro-
nary revascularisation and stroke were taken from a meta-
analysis of 14 randomised controlled trials of statin therapy.
Absolute risk reductions (ARR) between control and treatment
arms were calculated. Baseline LDL-C value of 3.6 mmol/L (SD
1.27) was taken from the Health Survey for England 2003 and
5000 LDL-C values 3.0 mmol/L and 2.0 mmol/L were ran-
domly generated from this distribution giving mean baseline
LDL-C values of 4.24 mmol/L and 3.86 mmol/L respectively.
Absolute LDL-C reductions needed to meet the alternative
targets were calculated and ARR in CV event incidence applied.
The % reduction in CV events for 1000 patients was used to
estimate number of CV events avoided; costs of events avoided
were calculated using the National Tariff 2007–08. RESULTS:
ARR between control and treatment arms was 1.8%, 1.8% and
0.6% for MI, coronary revascularisation and stroke respectively.
Absolute reduction required to meet the LDL-C target of
<3.0 mmol/L was 1.24 mmol/L resulting in 51 CV events
avoided (22 MIs; 22 CABG/PTCAs; 7 strokes), with a total cost
saving of £220,714 (MI = £70,158; CABG/PTCA = £130,368;
stroke = £20,188). The 1.86 mmol/L required to meet the LDL-C
target <2.0 mmol/L resulted in the 77 CV events avoided
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